Trial Profile
A Multicentre Observational Cohort Study of Northern Italy (LORHEN Registry) Comparing Efficacy and Retention Rate of Tocilizumab and Tumor Necrosis Factor Inhibitors Used in Combination with Methotrexate as First-Line Biologic Therapy in Rheumatoid Arthritis Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 16 Jun 2018 Results (n=242) presented at the 19th Annual Congress of the European League Against Rheumatism
- 05 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.